Please login to the form below

Not currently logged in
Email:
Password:

Ninlaro

This page shows the latest Ninlaro news and features for those working in and with pharma, biotech and healthcare.

ASH18: CAR-T and drugs give new options for multiple myeloma

ASH18: CAR-T and drugs give new options for multiple myeloma

Drug therapies. There was also plenty of new data available on drug therapies for myeloma, notably Takeda’s proteasome inhibitor Ninlaro (ixazomib) which looks on course to claim a new indication ... Ninlaro is already approved as a second-line therapy

Latest news

More from news
Approximately 3 fully matching, plus 11 partially matching documents found.

Latest Intelligence

  • Forging a path in specialty care Forging a path in specialty care

    Adcetris (for Hodgkin Lymphoma), Entyvio (for ulcerative colitis and Crohn's Disease) and future compound Ninlaro (an oral protease inhibitor for relapsed/refractory multiple myeloma) which was approved by the FDA

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics